At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effects of Febuxostat on Adipokines and Kidney Disease in Diabetic Chronic Kidney Disease
In Brief
A clinical study evaluating Febuxostat and Placebo for Chronic Kidney Disease and Diabetes. Completed, enrolled 80 participants across 1 site.
Detailed Summary
Hyperuricemia is emerging as a risk factor for development of diabetes and metabolic syndrome. Recently, it was shown in in-vitro cell culture experiments that hyperuricemia induces redox-dependent signaling and oxidative stress in adipocytes. By targeting levels of uric acid with febuxostat it is hypothesized that the levels of oxidative stress in adipose tissue (obtained by fat biopsy) will decrease. Primary aims of the study are to determine whether febuxostat therapy in overweight or obese, diabetic patients with stage 3 Chronic Kidney Disease (CKD) and high serum uric acid levels 1. will affect adipose tissue concentrations of thiobarbituric acid reactive substance (TBARS), a marker of oxidative stress 2. will affect adipose tissue expression and concentrations of adiponectin; and 3. will affect urinary concentrations of transforming growth factor (TGF)- B1.
Study Details
Timeline
Interventions
80 mg/day of febuxostat for 24 weeks
1 placebo tablet per day for 24 weeks